Detection of cardiac biomarker associated with structural heart disease, increased risk of death

December 07, 2010

With the use of a highly sensitive test, detection of the blood biomarker cardiac troponin T, a cardiac-specific protein, is associated with structural heart disease and an increased risk of all-cause death, according to a study in the December 8 issue of JAMA.

Cardiac troponin T (cTnT) is a preferred biomarker for the diagnosis of heart attack, and increasingly it has been recognized that elevated troponin levels may be detected in several chronic disease states, including coronary artery disease (CAD), heart failure, and chronic kidney disease (CKD). Some research has suggested that troponin may be useful for detecting subclinical cardiovascular disease and assessing cardiovascular disease risk in the general population; however, the low prevalence of detection with standard tests would limit the use of troponin measurement for these clinical applications, according to background information in the article.

"Recently, a highly sensitive assay for cTnT has been developed that detects levels approximately 10-fold lower than those detectable with the standard assay," the authors write. "In patients with chronic heart failure and chronic CAD, circulating cTnT is detectable in almost all individuals with the highly sensitive assay, and higher levels correlate strongly with increased cardiovascular mortality."

James A. de Lemos, M.D., of the University of Texas Southwestern Medical Center, Dallas, and colleagues conducted a study to determine the prevalence of detectable cTnT in the population using a highly sensitive assay and to assess whether cTnT levels measured with this new test were associated with cardiac abnormalities and subsequent death. Cardiac troponin T levels were measured using both the standard and the highly sensitive assays in 3,546 multiethnic individuals, ages 30 to 65 years, enrolled between 2000 and 2002 in the Dallas Heart Study. Mortality follow-up was complete through 2007. Participants were placed into 5 categories based on cTnT levels. Cardiac structure and function was measured with magnetic resonance imaging.

The researchers found that the prevalence of detectable cTnT in Dallas County adults was 25 percent using the highly sensitive cTnT assay and 0.7 percent using the standard assay. Large differences in prevalence were seen according to sex and race/ethnicity: men were 3-fold more likely to have detectable levels than women (37.1 percent vs. 12.9 percent), and black participants had a significantly higher prevalence of detectable cTnT than Hispanic or white participants. The prevalence of detectable cTnT also varied with age, ranging from 14 percent in participants ages 40 to 50 years to 57.6 percent in those 60 to 65 years.

Two-thirds of participants in the highest cTnT category had undetectable cTnT levels with the standard assay. The prevalence of hypertension increased from 27.2 percent to 70.9 percent and prevalence of diabetes from 7.7 percent to 41 percent across categories of increasing cTnT levels. Left ventricular mass increased markedly across cTnT categories, as did left ventricular wall thickness, and the proportion of individuals classified as having left ventricular hypertrophy (enlargement) increased from 7.5 percent to 48.1 percent. Self-reported heart failure, coronary heart disease, and cardiovascular disease were more frequent with higher cTnT levels.

During a median (midpoint) follow-up of 6.4 years, there were 151 total deaths, including 62 cardiovascular disease deaths. All-cause mortality increased from 1.9 percent to 28.4 percent across higher cTnT categories. After adjustment for several factors, cTnT category remained independently associated with all-cause mortality. "Prior studies have described associations between increased troponin levels detected with standard assays and future risk for mortality. Here, we report that these associations extend to much lower troponin levels not detected with assays in current clinical use," the authors write.

The authors suggest that their finding of a high prevalence of detectable cTnT in the general population may have important, and complex implications for the use of highly sensitive troponin assays for diagnosing heart attack in the hospital setting. "Among patients with clinical presentations suspicious for myocardial infarction, higher-sensitivity assays improve diagnostic sensitivity, particularly early after presentation, but reduce specificity. When applied to patients with a high clinical suspicion for myocardial infarction, the net result is improved accuracy."

These findings suggest that future studies should be performed to assess whether measurement of cTnT levels with a highly sensitive assay adds value to traditional cardiovascular risk factors, the researchers add.
(JAMA. 2010;304[22]:2503-2512. Available pre-embargo to the media at

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

To contact James A. de Lemos, M.D., call LaKisha Ladson at 214-648-3404 or email

For More Information: Contact the JAMA/Archives Media Relations Department at 312-464-JAMA or email:

The JAMA Network Journals

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to